FAKTOR-OPTIONSSCHEIN - ASTRAZENECA | Market Closed - Börse Stuttgart 03:28:01 29/05/2024 pm IST | ||
| 5.63 EUR | +6.43% |
|
| Current month | +6.23% | ||
| 1 month | +1.44% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 29/24/29 | 5.63 | +6.43% |
| 28/24/28 | 5.29 | +5.38% |
| 24/24/24 | 5.02 | +2.87% |
| 23/24/23 | 4.88 | -1.81% |
| 22/24/22 | 4.97 | -1.19% |
Delayed Quote Börse Stuttgart
Last update May 29, 2024 at 03:28 pm IST
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | Morgan Stanley |
| WKN | MG1848 |
| ISIN | DE000MG18480 |
| Date issued | 28/03/2024 |
| Strike | 15,035 p |
| Maturity | Unlimited |
| Parity | 6.43 : 1 |
| Emission price | 10 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 10.41 € |
|---|---|
| Lowest since issue | 4.86 € |
| Spread | 0.01 € |
| Spread % | 0.18% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
151.7
USD
Average target price
170.2
USD
Spread / Average Target
+12.19%
- Stock Market
- Certificates
- Certificat
